Impact Biomedical IBO
NYSE IBO
$5.14 +0.35 (+7.31%)
At close: Nov 13, 2026 · 4:00 PM EST

Impact Biomedical (IBO) Gross Margin (2025 - 2026)

Updated

Impact Biomedical's Gross Margin came in at 71.43% for Q3 2026, down 23.02 percentage points from 94.44% a year earlier but up 4.76 percentage points from the prior quarter.

Analysis

Impact Biomedical (IBO) Gross Margin (2025 - 2026) Analysis & Trends

Over the trailing twelve months to Sep 30, 2026, Impact Biomedical reported Gross Margin of -1002.63%; for FY2025, it was -1225.00%.

  • The five-year range for quarterly Gross Margin is -5928.57% (Q4 2025) to 94.44% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 83.88%
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 68.12%
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 75.38%
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 72.95%
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 88.03%
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 73.10%
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 81.07%
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 75.71%
10 Impact Biomedical 43.92 Mn 47.11 Mn 15,000.00 71.43%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 71.43%
Jun 30, 2026 66.67%
Dec 31, 2025 -5,928.57%
Sep 30, 2025 94.44%
Jun 30, 2025 85.71%
API Access

Impact Biomedical Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=IBO&period=max&api_key=YOUR_API_KEY